Related trials
Gardecki, 3000 - Ticlopidine vs placebo
Lyon-II, 3000 - Ticlopidine vs placebo
ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)
ADVANCE 3, 2010 - apixaban vs enoxaparin
RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)
DRIVE, 2008 - SR123781A vs enoxaparin
RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)
RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)
RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)
RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)
RECORD 1, 2008 - rivaroxaban vs enoxaparin
ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)
RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin
Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)
RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)
RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin
APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)
RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)
ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)
ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)
EXPRESS, 2003 - ximelagatran vs Enoxaparin
Platinum (Colwell), 2003 - ximelagatran vs Enoxaparin
PENTHIFRA�PLUS (Eriksson), 2003 - extended prophylaxis vs standard prophylaxis
PENTATHLON (Turpie), 2002 - fondaparinux vs enoxaparin
METHRO III, 2002 - ximelagatran vs Enoxaparin
See also:
All DVT prophylaxis clinical trials
All clinical trials of antithrombotics
All clinical trials of Acenocoumarol
|
|
Treatments
Studied treatment |
Acenocoumarol
|
Control treatment |
Reviparin 4200 anti-Xa IU x1
|
Patients
Method and design
Randomized effectives |
645 / 644 (studied vs. control) |
Blinding |
Open |
Follow-up duration |
6 weeks |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
Deep vein thrombosis
20 / 636
15 / 643
classic
1,35 [0,70;2,61]
Symptomatic pulmonary embolism
4 / 645
0 / 644
classic
16,97 [0,30;957,03]
Major bleeding
proximal DVT
4 / 636
3 / 643
classic
1,35 [0,30;6,00]
All cause death
2 / 645
0 / 644
classic
8,99 [0,14;559,07]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
Deep vein thrombosis
|
20 / 636 (3,1%) |
15 / 643 (2,3%) |
1,35 |
[0,70;2,61] |
|
|
Symptomatic pulmonary embolism
|
4 / 645 (0,6%) |
0 / 644 (0,1%) |
7,99 |
[0,42;150,79] |
|
|
proximal DVT
|
4 / 636 (0,6%) |
3 / 643 (0,5%) |
1,35 |
[0,30;6,00] |
|
|
All cause death
|
2 / 645 (0,3%) |
0 / 644 (0,1%) |
3,99 |
[0,18;88,40] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Deep vein thrombosis |
3,14% |
2,33% |
8,1‰
|
proximal DVT |
6,29‰ |
4,67‰ |
1,6‰
|
Meta-analysis of all similar trials:
anticoagulant in DVT prophylaxis for orthopedic surgery
antithrombotics in DVT prophylaxis for orthopedic surgery
Reference(s)
-
Samama CM, Vray M, Barr� J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D.
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant..
Arch Intern Med 2002;162:2191-6
Pubmed
|
Hubmed
| Fulltext
|